eli lilly tirzepatide news today says weight loss drug cuts heart failure risk by 38% in trial Powerful new obesity drug poised

While both agents struggled with the inherent GI burden typical of GLP-1RAs, efpeglenatides limitations were largely dose-related and within manageable expectations, whereas taspoglutides combination of severe immunogenicity and hypersensitivity reactions rendered it clinically unviable

What the clinical trials actually show about retatrutide and fatigue Numbers matter here because they put your experience in context

A medication that reduces alcohol consumption as a side effect of treatment for other conditions like obesity could reach this population in ways that traditional addiction treatments cannot

Roughly 10 million Americans live with some form of it, according to a recent paper tracking U.S